Patent Expirations Expected to Cause Boom in Biosimilars Market

Publication
Article
Specialty Pharmacy TimesMarch/April 2014
Volume 5
Issue 2

The global biosimilars market is projected to experience significant growth over the next several years, according to a report from TechNavio.

The report, Global Biosimilars Market 2014-2018, says several factors could influence a projected compound annual growth rate of 27.58% in the global biologics market through 2018. The catalyst for the expected boom is an increasing number of expiring patents.

Blockbuster drugs whose patents are due to expire include Remicade, Humira, and Retuxan.

The report also notes that the risk of drug failure after launch is a key challenge for companies involved in the development of biosimilar drugs.

The full report is available through Research and Markets.

About the Author

Davy James is the associate editor of Specialty Pharmacy Times. He can be reached at djames@pharmacytimes.com.

Recent Videos
Patient taking prescription medicine -- Image credit: Rawpixel.com | stock.adobe.com
Biosimilar pharmaceutical drug bottle on blue background. | Image Credit: Carl - stock.adobe.com
BIOSIMILARS - pharmaceutical concept | Image Credit: hafakot - stock.adobe.com
Pharmacist selling medications in the pharmacy | Image Credit: rh2010 - stock.adobe.com
Laboratory test tubes and solution with stethoscope background | Image Credit: Shutter2U - stock.adobe.com
Portrait of young female pharmacist holding medication while using computer at pharmacy counter | Image Credit: Dragana Gordic - stock.adobe.com
biosimilar word or concept represented by wooden letter tiles on a wooden table with glasses and a book | Image Credit: lexiconimages - stock.adobe.com
Laboratory test tubes and solution with stethoscope background | Image Credit: Shutter2U - stock.adobe.com
Laboratory test tubes and solution with stethoscope background. Science and Medical concept. Scientist research and analysis biotechnology concept - Image credit: Shutter2U | stock.adobe.com
Health care professional holding adalimumab